A Phase I Dose Escalation Trial Of Pt2385, A First-In-Class Oral Hif-2a Inhibitor, In Patients With Advanced Clear Cell Renal Cell Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY（2016）
Key words
Tumor Hypoxia
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined